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Introduction
Spinal cord injury (SCI) rostral to the lumbosacral level
causes lower urinary tract dysfunctions, including detru-
sor hyperreflexia, incontinence, autonomic dysreflexia
and detrusor-sphincter dyssynergia.1–6 Intravesical or
systemic administration of capsaicin or resiniferatoxin in
SCI cats and rats reduced detrusor hyperreflexia, unin-
hibited bladder contractions and vesicovascular reflexes,
indicating that these disorders are triggered, at least
in part, by capsaicin-sensitive C-fiber bladder afferents.
These afferents also appear to contribute to neurogenic
bladder dysfunction in humans, since the intravesical
administration of capsaicin or resiniferatoxin in patients
with SCI or multiple sclerosis decreases detrusor hyper-
activity and the number of incontinence episodes.
In normal animals, a considerable proportion of
bladder C-fiber afferents are chemosensitive but insensi-
tive to mechanical stimuli (i.e. silent C-fiber afferents)
and are, therefore, unresponsive to bladder distension
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and make no contribution to micturition reflexes.
However, following SCI, the electrical and morpho-
logic properties of bladder afferent neurons change.
The afferents become mechanosensitive and can initi-
ate bladder reflexes. It has been speculated that neu-
rotrophic factors, such as the nerve growth factor or
other chemicals released in the bladder, may be respon-
sible for the afferent nerve plasticity after SCI.
Among the various chemicals known to modulate
the activity of bladder afferent nerves, adenosine triphos-
phate (ATP) has recently been the subject of much
attention. A subpopulation of C-fiber bladder afferent
nerves exhibit P2X2 and P2X3 purinergic receptors7–9
and are excited by exogenous ATP administered intra-
vesically by in vivo preparations or when applied to
the bladder in vitro. ATP, which is released from the
urothelium by mechanical or chemical stimuli, may
act on the C-fiber afferents that are located adjacent to
or within the urothelium and, thereby, induce reflex
bladder activity. Mice in which the P2X3 receptor has
been knocked out exhibited hypoactive bladders10–12
and decreased bladder excitatory responses to the
intravesical administration of ATP. Because the P2X3
receptors are expressed exclusively in afferent nerves,
these data suggest that purinergic afferent mechanisms
play an important role in reflex voiding in mice.
In the present study, we examined the effect of a
recently developed potent and selective non-nucleotide
P2X3 and P2X2/3 purinergic receptor antagonist
(A-317491) on voiding function in chronic spinal cord-
injured rats to determine if ATP contributes to neuro-
genic detrusor overactivity.
Methods
Spinal cord transection and care of SCI rats
Six chronic spinal cord transected female Sprague-
Dawley rats (290–336g) were used in this study. Spinal
transections at the T8–T9 segmental level were per-
formed using aseptic techniques under halothane anes-
thesia. After a T9–T10 laminectomy, the dura matter
was cut and the spinal cord transected with scissors,
after which the point of a 16-gauge needle was moved 
6 times around the inner surface of the exposed verte-
bra to ensure complete transection. Then, a piece of
sterile sponge (Gelfoam; The Upjohn Company,
Kalamazoo, MI, USA) was placed between the 2 cut
ends of the spinal cord and the overlying muscle and
skin were sutured. The rats were kept in a room in
which the temperature was maintained at 23–23.5°C,
and they were treated with antibiotics (ampicillin
150mg/kg, intramuscular) every 2 days for 10 days.
The bladders were manually compressed 2 or 3 times
daily after spinal transection to prevent over-distension
of the bladder and infection. Perigenital stimulation
with a cotton swab was used to activate a somatovesical
reflex pathway and promote bladder emptying.13
Cystometric studies
Fourteen to 16 weeks after spinal transaction, cystome-
try was performed on the same animals. The rats were
anesthetized with 2% halothane, and then the jugular
vein was cannulated for drug and fluid administration.
The bladder was exposed via a midline abdominal inci-
sion. The bladder end of a polyethylene catheter (inner
diameter 0.76 mm, outer diameter 1.22 mm; Clay-
Adams, Parsippany, NJ, USA) was heated to create a
collar and passed through a small incision at the bladder
dome. A 3-0 surgical silk suture (Ethicon, Somerville,
NJ, USA) was tightened around the collar of the
catheter. The cystostomy catheter was placed inside a
larger polyethylene tube that acted as a tunnel to pre-
vent the bending of the cystostomy catheter during the
experiment. After the closure of the abdominal wound,
the rats were placed in a restraining cage (Ballman
Cage) in a normal crouched posture and allowed to
recover from the halothane anesthesia for 1–2 hours
before the experiment. The cystostomy catheter was
connected to an infusion pump (model 55-4150;
Harvard Apparatus, Holliston, MA, USA) to allow the
continuous infusion of physiologic saline at room tem-
perature into the bladder. Bladder pressure was moni-
tored during cystometry by connecting the bladder
catheter to a Statham pressure transducer. Continuous
cystometrograms (CMGs) were performed using a con-
stant infusion (0.2mL/min) of saline into the bladder
to induce repetitive voiding.14 The infusion of saline
continued for at least 2 hours before the control voiding
parameters were measured. Several control CMGs were
performed on the same animal. Body temperature was
monitored and maintained within the range of 36–38°C
through an external heating device.
Drug administration
A-317491, a selective P2X3 purinergic receptor antago-
nist, was administered intravenously in the cystometry
studies, at increasing doses of 0.03, 0.1, 0.3, 1, 3, 10
and 30 µmol/kg at 40–50 minute intervals. CMGs
were measured before and after the administration of
each dose of the drug.
Statistical analysis
The quantitative data are presented as mean ± standard
error. Wilcoxon signed rank test was used to compare
each parameter before and after drug administration.
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A value of p < 0.05 was taken to indicate a significant
difference.
Results
Control urodynamic measurements
During the surgical procedure to insert the cystostomy
catheter to conduct the CMGs, it was clear that all of
the SCI rats exhibited severely distended and hyper-
trophied bladders. CMGs revealed a large number of
small-amplitude (> 8 cmH2O) non-voiding contrac-
tions (NVCs) (average, 9.7 per voiding cycle) during
the saline infusion. Voiding contractions (mean ampli-
tude, 31cmH2O; duration, 2.5 minutes) occurred at an
average interval of 539 seconds, equivalent to approx-
imately 1.8 mL of infused saline between voids. The
average pressure threshold for inducing voiding con-
tractions was 5.7 cmH2O. The mean bladder capacity
was calculated from the sum of the residual volume
and infusion volume, which was 2.5 mL during CMGs.
Repeated CMGs performed over 1–2 hour intervals
in the same animal yielded reproducible filling and
voiding parameters.
Effect of A-317491 on voiding and 
bladder activity
After obtaining control CMGs, A-317491 was admin-
istered intravenously in increasing doses, from 0.03 to
30µmol/kg. The interval between voiding contractions
(intercontractile interval) did not significantly change
after smaller doses of the drug (0.03–0.3µmol/kg), but
increased significantly (p < 0.05) after 1–30 µmol/kg
of A-317491 (from 539 to 655–676 seconds) (Figures
1 and 2). The mean number of small-amplitude
(≥8cmH2O) NVCs which occurred between the void-
ing contractions significantly decreased after 1–30
µmol/kg of the drug had been administered (from
9.72 to 5.6, 4.6, 4.75 and 3.63, respectively, p < 0.05),
but did not change significantly following smaller doses
(0.03–0.3µmol/kg) (Figures 1 and 3). The pressure
threshold for inducing voiding increased after 1–30
µmol/kg of A-317491 (from 5.73 to 8.76, 9.91,
9.74 and 9.72, respectively, p < 0.05), but was not sig-
nificantly changed following smaller doses (Figures 
1 and 4). The amplitude, duration of voiding contrac-
tions and baseline bladder pressure were not affected
by any doses of the drug (Figures 5 and 6). The effect
of A-317491 was apparent within 10–15 minutes
after administration, and, after the largest dose of the
drug, persisted for the duration of the experiment
(2–3 hours).
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Figure 1. Cystometrograms showing the effects of A-317491 on
voiding and bladder activity.
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Figure 2. Intervals of effective contraction (intercontractile
interval, ICI) before and after intravenous P2X3 receptor antagonist
administration in cystometry study (n = 6). *p < 0.05.
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Figure 3. Number of non-voiding contractions (NVCs) before and
after intravenous P2X3 receptor antagonist administration in
cystometry study (n = 6). *p < 0.05.
Discussion
The present experiments revealed that the systemic
administration of A-317491, a P2X3–P2X2/3 receptor
antagonist, during continuous fast-infusion cystometry
in conscious, chronic SCI rats reduced the number of
non-voiding bladder contractions, increased the intra-
vesical pressure threshold for inducing voiding and also
increased the interval between voids without altering
the amplitude or duration of the voiding contractions.
The drug also decreased the frequency of voiding and
increased the volume of urine per void without affect-
ing total urine excretion under conditions of natural
bladder filling in SCI animals held in a metabolism cage.
These results indicate that purinergic mechanisms or
P2X3 or P2X2/3 receptors on bladder afferent nerves
play an important role in detrusor hyperreflexia due
to SCI.
A-317491 is a non-nucleotide purinergic receptor
antagonist that competitively blocks recombinant
human and rat P2X3 and P2X2/3 receptors with a 100-
fold selectivity over other types of P2X receptors. The
drug exhibits very weak or no affinity for a large selec-
tion of other cell surface receptors and ion channels.
Recent studies reveal that the drug also blocked native
P2X3 and P2X2/3 receptors in rat dorsal root ganglion
cells and dose-dependently reduced complete Freund’s
adjuvant-induced thermal hyperalgesia (ED50 = 30
µmol/kg, subcutaneous), attenuating both the thermal
hyperalgesia and mechanical allodynia (ED50 = 10–15
µmol/kg, subcutaneous) following chronic nerve
constriction injury. These data, coupled with other
reports indicating the presence of P2X2/3 receptors in
IB4-positive C-fiber afferent neurons, indicate that
purinergic mechanisms are involved in the peripheral
and central sensitization of C-fiber nociceptors in
chronic inflammatory and neuropathic pain. In the
present experiments, similar doses of A-317491
reduced the frequency of voiding as well as the pres-
sure threshold for inducing voiding without affecting
maximal micturition pressure. This suggests that the
drug suppressed the afferent limb of the spinal mic-
turition reflex without altering the efferent limb of
the reflex or the properties of the bladder detrusor
muscle.
The CMG measurements in SCI female rats in the
present study were similar to those obtained previously
in awake SCI female rats. The most prominent changes
following SCI were an increase in bladder capacity
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Figure 4. Pressure threshold (PT) before and after intravenous
P2X3 receptor antagonist administration in cystometry study
(n = 6). *p < 0.05.
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Figure 5. Amplitude of effective bladder contraction (BCA) before
and after intravenous P2X3 receptor antagonist administration in
cystometry study (n = 6).
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Figure 6. Duration of effective bladder contraction (BCD) before
and after intravenous P2X3 receptor antagonist administration in
cystometry study (n = 6).
(2.5 mL vs. 1 mL in awake spinal cord-intact rats) and
the presence of large numbers of NVCs prior to mic-
turition. Although these changes were probably due to
the spinal injury, it is also possible that some changes
were related to the abdominal surgery and insertion
of the bladder catheter on the day of the experiment or
the fast infusion rate in cystometry.
The chronic transection of the thoracic spinal cord
induces significant changes in the cystometric para-
meters of conscious female rats, including the appear-
ance of uninhibited bladder contractions before the
onset of micturition and obstructed voiding and
decreased voiding efficiency.15 The present study reveals
that A-317491 was effective in increasing the intercon-
tractile interval and volume threshold, and in decreasing
the number of NVCs in long-term SCI rats. However,
the drug did not alter the amplitude and duration of
voiding bladder contractions. This indicates that the
drug did not alter the contractility of the detrusor mus-
cle or the efferent pathways to the bladder.
Cockayne et al12 reported that conscious or anes-
thetized P2X3-null mice also had significantly decreased
micturition frequencies and increased bladder capaci-
ties, although their voiding bladder pressures were
not reduced. These data suggest that the P2X3-null
mice had a sensory rather than a motor defect in the
bladder.
The rat bladders in this study were hypertrophied
and enlarged following long-term SCI. It has been
proposed that animals with a larger volume threshold
tend to have a higher pressure threshold, indicating that
the more distended bladders require a higher intramu-
ral tension to stimulate the afferent fibers, or that
higher levels of afferent firing are needed to trigger 
a micturition reflex. However, the pressure threshold
before treatment in this study was lower than that 
of the normal rats (5.73 vs. 13 cmH2O).16 This indi-
cates that the micturition reflex is triggered more eas-
ily due to the increased excitability of the afferent
nerves, despite the hypertrophied and enlarged blad-
ders following SCI.
In the present study, CMGs were performed in
conscious rats. It was reported that urethane affected
the central transmitter mechanisms involved in the
micturition reflex and decreased the voiding effi-
ciency and volume threshold for inducing micturition
in normal rats.17,18 Urethane was also reported to
completely depress reflex micturition in chronic SCI
rats.19 Thus, SCI rats appear to increase the sensitivity
of their micturition reflex to urethane.20 Therefore, it
would be better to test the CMGs in conscious
awake animals in this study rather than urethane-
anesthetized ones.
The bladder catheter was inserted through a dome
in this study, which may have eliminated the impact of
bladder outlet obstruction produced by a transurethral
catheter.21 Nevertheless, the disadvantages of this trans-
vesical catheterization method may be the possible
irritation of the bladder, and the limitation of bladder
movement during filling and voiding. However, this
irritation change was not evident during the first day
following transvesical catheterization. Therefore, this
procedure is best for acute experiments immediately
after catheter implantation22 or experiments pursued at
least 6–7 days after implantation.23 Thus, the results of
the CMGs that we performed on the same day as the
transvesical catheterization in this study should be
reliable.
Some previous studies measured the voided volume
and residual volume, and subsequently calculated the
bladder capacity and voiding efficiency24,25 of SCI rats.
However, the measurements of voided volume and
residual volume are relatively subjective, and it is diffi-
cult to measure these parameters accurately for con-
scious animals in the Ballman cage. Actually, Yoshiyama
et al also found that bladder capacity varied consider-
ably from 0.33 to 3.3mL within the SCI group.24
Nevertheless, in the present study, the rat bladders
appeared consistently hypertrophied and enlarged in all
animals. Thus, we did not measure the voided volume
or the residual volume in this experiment.
Previous clinical studies reported that the intraves-
ical administration of capsaicin or resiniferatoxin pro-
duced clinical improvements in neurogenic bladder
conditions, such as incontinence and detrusor hyper-
reflexia, in SCI and multiple sclerosis patients,26–29 as
well as hypersensitive bladder dysfunction in intersti-
tial cystitis.30 This study revealed that A-317491 inhib-
ited reflex bladder hyperactivity including non-voiding
detrusor contractions without affecting voiding con-
tractility, which is similar to the delayed suppressed
effects elicited by intravesical capsaicin or resinifera-
toxin administration. Thus, A-317491 may provide a
new alternative treatment for the above pathologic con-
ditions. The possibility of oral administration is the
obvious advantage of A-317491 over intravesical instil-
lation of capsaicin or resiniferatoxin. In clinical terms,
the intravesical administration of capsaicin can pro-
duce suprapubic pain, burning, macroscopic hema-
turia, or increased incontinence during the first week
after treatment.30 Therefore, after conducting further
clinical trials to validate the efficacy and side effects,
A-317491 may be a better treatment of choice for
neurogenic bladder disorders related to bladder afferent
excitability, such as SCI, multiple sclerosis and inter-
stitial cystitis.
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